NCT07302607 Predictive Factors of Complete Response to Immunotherapy in Metastatic Melanoma: a Single-center Retrospective Study Between 2013 and 2021
| NCT ID | NCT07302607 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Strasbourg, France |
| Condition | Stage III Melanoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 221 participants |
| Start Date | 2024-12-11 |
| Primary Completion | 2026-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 221 participants in total. It began in 2024-12-11 with a primary completion date of 2026-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Although impressive progress has been made with this new therapeutic strategy, only a proportion of patients achieve a complete and sustained response. Studies have already identified predictive factors of treatment response that are now widely recognized. In this study, the investigators aim to identify other response factors not yet evaluated in the literature.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years; * Unresectable stage III or stage IV melanoma according to the AJCC classification - 8th edition; * Curative immunotherapy treatment (anti-PD-1 and/or anti-CTLA-4); * Treatment and follow-up at the Dermatology Department of the Strasbourg University Hospitals; * Immunotherapy initiated between January 1, 2013, and December 31, 2021. Exclusion Criteria: * Primary choroidal melanoma; * Adjuvant-intent immunotherapy; * Less than 3 months of follow-up after the start of immunotherapy; * Change of treatment before the first reassessment; * Treatment and follow-up at a department other than the Dermatology Department of the Strasbourg University Hospitals.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07302607 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stage III Melanoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07302607 currently recruiting?
Yes, NCT07302607 is actively recruiting participants. Contact the research team at cedric.lenormand@chru-strasbourg.fr for enrollment information.
Where is the NCT07302607 trial being conducted?
This trial is being conducted at Strasbourg, France.
Who is sponsoring the NCT07302607 clinical trial?
NCT07302607 is sponsored by University Hospital, Strasbourg, France. The trial plans to enroll 221 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.